RS60122B1 - Kombinovane terapije za lečenje hemorezistentnih kancera - Google Patents

Kombinovane terapije za lečenje hemorezistentnih kancera

Info

Publication number
RS60122B1
RS60122B1 RS20200355A RSP20200355A RS60122B1 RS 60122 B1 RS60122 B1 RS 60122B1 RS 20200355 A RS20200355 A RS 20200355A RS P20200355 A RSP20200355 A RS P20200355A RS 60122 B1 RS60122 B1 RS 60122B1
Authority
RS
Serbia
Prior art keywords
compound
cancer
hypomethylating agent
formula
dna hypomethylating
Prior art date
Application number
RS20200355A
Other languages
English (en)
Serbian (sr)
Inventor
Daniel P Gold
Guillermo Garcia-Manero
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of RS60122B1 publication Critical patent/RS60122B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RS20200355A 2012-10-30 2013-10-30 Kombinovane terapije za lečenje hemorezistentnih kancera RS60122B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720346P 2012-10-30 2012-10-30
PCT/US2013/067607 WO2014070948A1 (en) 2012-10-30 2013-10-30 Combination therapies
EP13851971.5A EP2914254B1 (en) 2012-10-30 2013-10-30 Combination therapies to treat chemoresistant cancers

Publications (1)

Publication Number Publication Date
RS60122B1 true RS60122B1 (sr) 2020-05-29

Family

ID=50628036

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200355A RS60122B1 (sr) 2012-10-30 2013-10-30 Kombinovane terapije za lečenje hemorezistentnih kancera

Country Status (16)

Country Link
US (2) US20150258068A1 (enExample)
EP (2) EP2914254B1 (enExample)
JP (1) JP6343285B2 (enExample)
CA (1) CA2927565C (enExample)
CY (1) CY1123043T1 (enExample)
DK (1) DK2914254T3 (enExample)
ES (1) ES2774296T3 (enExample)
HR (1) HRP20200521T1 (enExample)
HU (1) HUE048584T2 (enExample)
LT (1) LT2914254T (enExample)
PL (1) PL2914254T3 (enExample)
PT (1) PT2914254T (enExample)
RS (1) RS60122B1 (enExample)
SI (1) SI2914254T1 (enExample)
SM (1) SMT202000168T1 (enExample)
WO (1) WO2014070948A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101127201B1 (ko) 2003-09-22 2012-04-12 에스*바이오 피티이 리미티드 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
EP4317972A3 (en) 2018-02-06 2024-03-13 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
MA54322A (fr) * 2018-11-30 2021-10-06 Mei Pharma Inc Polythérapies pour mds à haut et très haut risque

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20100098691A1 (en) * 2001-01-24 2010-04-22 S'bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
JP2005517007A (ja) 2002-02-07 2005-06-09 アクシス・ファーマスーティカルズ ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
EP1937650B1 (en) * 2005-09-08 2011-06-15 S*BIO Pte Ltd Heterocyclic compounds
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP2012503651A (ja) * 2008-09-26 2012-02-09 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ３−デアザネプラノシン誘導体

Also Published As

Publication number Publication date
HUE048584T2 (hu) 2020-08-28
EP2914254A1 (en) 2015-09-09
CY1123043T1 (el) 2021-10-29
EP2914254A4 (en) 2016-06-29
LT2914254T (lt) 2020-04-27
EP2914254B1 (en) 2020-01-08
EP3662911A1 (en) 2020-06-10
SI2914254T1 (sl) 2020-07-31
JP2016501838A (ja) 2016-01-21
ES2774296T3 (es) 2020-07-20
CA2927565A1 (en) 2014-05-08
CA2927565C (en) 2021-05-18
PT2914254T (pt) 2020-04-02
PL2914254T3 (pl) 2020-09-07
US20150258068A1 (en) 2015-09-17
JP6343285B2 (ja) 2018-06-13
US20210100775A1 (en) 2021-04-08
SMT202000168T1 (it) 2020-05-08
DK2914254T3 (en) 2020-03-30
WO2014070948A1 (en) 2014-05-08
HRP20200521T1 (hr) 2020-08-07

Similar Documents

Publication Publication Date Title
EP2914254B1 (en) Combination therapies to treat chemoresistant cancers
JP5907396B2 (ja) 腫瘍融解症候群の治療薬及び予防薬
CN101910182B (zh) 抗癌剂
US20170273952A1 (en) Methods of treating liver disease
ES2978930T3 (es) Moduladores de los receptores de arilo y procedimientos de fabricación y utilización de los mismos
TWI620565B (zh) 治療及預防移植物抗宿主病之方法
CN112654350A (zh) 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
JP2025118595A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
AU2017273771A1 (en) Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
CN112292128A (zh) Ep4抑制剂和其用途
JP2020533332A (ja) 障害を処置するためのｃｘｃｒ−２阻害剤
CN107001467A (zh) C‑c趋化因子受体9型(ccr9)的抑制剂和抗alha4beta7整联蛋白阻断抗体的组合治疗
EP2124997B1 (en) Use of il-1 antagonists to treat gout and pseudogout
WO2018007878A1 (en) Methods of treating and preventing gout and lead nephropathy
US10428059B2 (en) Compounds and methods of treating or ameliorating an IL-1R-mediated disease or disorder using same
CN114869897B (zh) 小分子化合物和硼替佐米在制备治疗多发性骨髓瘤药物中的应用
JP2021105005A (ja) 癌治療
ES2974842T3 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp
WO2022221586A1 (en) Combination therapy comprising a pkc inhibitor and a mek inhibitor
CA2914742A1 (en) Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception
JP2022552975A (ja) 関節リウマチを予防及び／又は治療するためのニコチンアミドモノヌクレオチド（ｎｍｎ）の使用、並びに対応する組成物
TW201343169A (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
KR20240158958A (ko) 암의 치료 및/또는 관리를 위한 stat 억제제와 면역 체크포인트 억제제의 조합
TW201924721A (zh) 包含pi3激酶抑制劑與bcl-2抑制劑的組成物
CN104606189B (zh) 一种化合物在制备mTOR抑制剂中的应用